Learn how Biointron's AbDrop™ speeds can revolutionize antibody discovery using Single B technology in the webinar recording!
Biointron is excited to announce our upcoming collaborative webinar with the Antibody Society, scheduled for June 26th, 2025. This webinar will feature our speaker, Dr. Gang Liu, Associate Director of Biointron. Dr. Liu will delve into the captivating topic of "AbDrop™ Speeds: Accelerating Your Antibody Discovery with Single B Solution," providing attendees with a rich and informative exploration of the latest trends and advancements in antibody discovery technologies. This webinar presents a not-to-be-missed opportunity for professionals, scholars, and all those passionate about the evolving landscape of antibody development, offering a chance to deepen their knowledge and engage with groundbreaking concepts in this vital field.
The seemingly agreeable path of antibody drug development from discovery to market in the modern world is actually filled with what-ifs, in many cases due to inadequate antibody molecules that are robust and “smart” enough to meet the ever-increasing research and clinical requirements. Single B cell screening is an up-to-date antibody discovery strategy that, unlike hybridoma technology, screens primary B cells to obtain diverse antibody candidates. As introduced in the presentation, Biointron’s single B cell screening platform (AbDrop™) is a microfluidic technology-driven, droplet-based, high throughput single B platform for antibody discovery. Integrated with high throughput NGS sequencing and antibody production capacity, AbDrop™ solution achieves antibody discovery goals in a timeline-expediting and diversity-protecting manner. As case studies presented demonstrate, this solution is especially effective for discovery campaigns like challenging targets, rare antibodies, and unique research requirements.
Dr. Gang Liu is Associate Director of Biointron. He has devoted himself to biological sciences and antibody therapeutics research for more than 20 years. Before joining Biointron, Dr. Liu worked in renowned biotech such as Genscript, and prestigious academia institutions, including Childrens Hospital LA, UC Irvine, and City of Hope Medical Center. Dr. Liu earned his Ph.D. degree from Academy of Military Medical Sciences in China, 2007.
AI is transforming antibody discovery, but better models only come from better d……
The antibody therapeutics sector is rapidly evolving, transitioning from traditi……
Biointron’s 2026 Lunch & Learn, held at CIC Cambridge on May 8, 2026, featured e……
This webinar provides an overview of Antibody-Drug Conjugates (ADCs) and expande……
You can also contact us on the Scientist and Science Exchange marketplaces.
